United States

Back to map

Showing 221-230 of 334 grants

Title Institution Researcher Program Duration Total Award Amount
Investigating MAFA governed mechanisms underlying β-cell functional maturation and dysfunction using hPSC-derived β-cells The Regents of the University of California, San Francisco Veronica Cochrane Cures 01-July-2024 to 28-February-2027 $231,222.03
Prediction of Cancer Immunotherapy Precipitated Autoimmune Diabetes The Regents of the University of California, San Francisco Zoe Quandt Cures 01-March-2025 to 28-February-2030 $1,000,000.00
Triple therapy for T1DM with insulin, semaglutide and dapagliflozin The Research Foundation of SUNY on behalf of University at Buffalo Paresh Dandona Improving Lives 01-January-2019 to 31-March-2026 $1,808,522.70
Project Equity The Sonia Nabeta Foundation Vivian Nabeta Mission 01-May-2024 to 30-April-2026 $245,172.00
Dissecting HLA Mechanisms in T1D, SLE, and MS Through High-Throughput Self-Antigen Profiling The University of Chicago Aly Khan Cures 01-September-2025 to 31-August-2026 $150,000.00
Investigating the role of integrated stress response in type 1 diabetes The University of Chicago Charanya Muralidharan Cures 01-March-2023 to 28-February-2026 $209,066.00
Development of β-Cell Targeted Lipid Nanoparticle Therapeutics The University of Chicago Jacob Ryan Enriquez Cures 01-March-2025 to 29-February-2028 $247,790.00
Safety and efficacy assessment of Tegoprubart and calcineurin inhibitors- free immunosuppression therapy for pancreatic islet transplantation in patients with t1DM and chronic kidney disease. The University of Chicago Piotr Witkowski Cures 01-September-2025 to 31-August-2029 $8,500,000.00
A pilot study assessing the safety of using a monoclonal antibody against CD40 ligand to achieve a calcineurin inhibitor-free immunosuppression regimen in patients with type 1 diabetes mellitus (T1D) and problematic hypoglycemia undergoing islet cell transplantation The University of Chicago Piotr Witkowski Cures 01-February-2024 to 31-January-2026 $250,000.00
A pilot study assessing the safety of using a monoclonal antibody against CD40 ligand to achieve a calcineurin inhibitor-free immunosuppression regimen in patients with type 1 diabetes mellitus (T1D) and problematic hypoglycemia undergoing islet cell transplantation The University of Chicago Piotr Witkowski Cures 01-February-2025 to 31-January-2027 $1,000,000.00